You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港交所(00388.HK)歐冠昇:持續研究推出18A章相關ETF及結構性產品
阿思達克 09-01 10:50
港交所(00388.HK)集團行政總裁歐冠昇指出,自2018年起已有超過100家生科企在香港主板上市,集資逾2,600億元,2020年互聯互通擴容,符合條件的未盈利生物科技公司獲納入合資格投資標的,以及近年來推出ETF、期貨及期權等投資產品亦為生物科技板塊帶來支持。 他表示,生物科技股已成為香港市場重要一環,現時有效上市申請中有近40家為相關企業,分析預期全球生物科技市場規模將由2020年的7,530億美元,增長至2030年的1.7萬億美元,交易所將致力提升市場流動性,促進資本活力,以支持中小市值公司發展,包括持續研究推出與18A章相關的ETF及結構性產品,以滿足投資者需求。 啟明創投主管合夥人梁(穎)宇透露,市場波動影響,上半年生物科技相關的私人市場融資金額有所下降,但宗數卻上升,反映投資者轉向投資更多更早期研發項目,該行60%投資公司過去一年均有獲得融資,有信心當IPO窗口恢復後,會有不少優質企業排隊上市。 港交所主席史美倫表示,環境、社會和管治(ESG)已成為全球共同目標,各國正攜手面對氣候變化、食品安全、人口老齡化及新興傳染病等問題,疫情加速醫療健康行業變革,數字醫療產業、健康數據一體化、居家治療等成為新常態,均正改變人類的未來發展,而亞太區特別是中國更是新興產業先行者,相信香港可擔任資本、技術及人才的樞紐。 她指出,港交所推行上市改革,讓未盈利生物科技企業接觸到國際資本,港府亦已承諾提供100億元支持產業長期商業化發展,交易所未來將與持份者及監管機構持續探討優化市場架構。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account